Company profile: Renaissance Pharma
1.1 - Company Overview
Company description
- Provider of clinical-stage pharmaceutical development focused on life-changing therapies in pediatric rare diseases, including Hu14.18K322A (Hu14.18), a humanized anti-GD2 antibody developed for treating high-risk neuroblastoma, showing improved survival rates when combined with chemotherapy.
Products and services
- Pediatric Rare Disease Therapy Development: Clinical-stage program develops life-changing therapies in pediatric rare diseases, with focused development on treatments for children with rare conditions
- Pediatric Neuroblastoma Therapy Advancement: Rare-disease-focused development centers on high-risk neuroblastoma, leveraging anti-GD2 targeting combined with chemotherapy to enhance survival outcomes
- Hu14.18K322A (Hu14.18): Humanized anti-GD2 monoclonal antibody engineered to treat high-risk neuroblastoma, demonstrating improved survival when combined with chemotherapy in patients
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Renaissance Pharma
Vitara
HQ: United States
Website
- Description: Provider of a therapeutic platform for premature infants that mimics natural physiological processes to improve survival and quality of life; the EXTEND extra-uterine system delivering womb-like support to study development with potential clinical applications; and artificial placenta and womb technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vitara company profile →
Viridian Pharma
HQ: United Kingdom
Website
- Description: Provider of niche pharmaceutical products for hospital use, developed and marketed in the UK. Established in 2002 and now part of Martindale Pharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Viridian Pharma company profile →
iScreen Vision
HQ: United States
Website
- Description: Provider of pediatric vision photoscreening devices and services, featuring the iScreen Vision Screener 3000 to detect major amblyopia risk factors and other serious eye problems through digital imaging, certified analysis of captured images, on-site and remote training, billing and customer support, and a 30-day risk-free trial with training, billing help, and regular check-ins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iScreen Vision company profile →
NeoLight
HQ: United States
Website
- Description: Provider of neonatal medical devices and education, including Skylife phototherapy beds with a 3D Light Array for treating newborn jaundice; ICON retinal imaging cameras for ROP screening with Direct Illumination; the portable ICON GO; P.A.L. technology supporting non-nutritive sucking to aid oral feeding progression; and the C.A.R.E.S. continuing medical education program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeoLight company profile →
Owlet
HQ: United States
Website
- Description: Provider of smart baby monitoring solutions, including the FDA-cleared Dream Sock that tracks infants’ pulse rate and oxygen levels with caregiver notifications; the Owlet Cam for live video and audio monitoring; and BabySat, a prescription pulse oximetry device for real-time monitoring of pulse rate and oxygen saturation under physician supervision.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Owlet company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Renaissance Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Renaissance Pharma
2.2 - Growth funds investing in similar companies to Renaissance Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Renaissance Pharma
4.2 - Public trading comparable groups for Renaissance Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →